Asthalin

Salbutamol sulfate

Symptomatic relief of asthma & prevention of symptoms in circumstances recognised by patient to precipitate asthma attack (eg, before exercise or unavoidable allergen exposure). Treatment of reversible component of airways obstruction.

Max recommended dose: 8 inhalations in 24 hr. Adult & childn ≥12 yr Symptomatic relief of acute asthma or reversible component of airways obstruction Initially 1 inhalation as single dose, may be increased to 2 inhalations if necessary. Prevention of allergen- or exercise-induced symptoms 2 inhalations 10-15 min before challenge. Chronic therapy 2 inhalations up to qds. Childn <12 yr Relief of acute bronchospasm 1 inhalation, may be increased to 2 inhalations if required. Prevention of allergen- or exercise-induced bronchospasm 1 inhalation before challenge or exertion, may be increased to 2 inhalations if required. Chronic therapy Up to 2 inhalations qds.

Hypersensitivity. Use in arresting uncomplicated premature labour & threatened abortion.

Ensure that aerosol actuation is synchronised w/ inspiration of breath for optimum delivery of active substance to lungs. Monitor patient's response clinically & by lung function tests. Patients who are prescribed regular anti-inflammatory therapy (eg, inhaled corticosteroids) should continue taking their anti-inflammatory medication even when symptoms decrease & Asthalin inhaler is not required. Increased use indicates deterioration of asthma control. Overuse may mask progression of underlying disease & contribute to deteriorating asthma control, leading to increased risk of severe asthma exacerbations & mortality. Patients should seek medical advice if a previously effective dose ceases to be effective for at least 3 hr, &/or their asthma seems to be worsening. Patients requiring long-term management should be kept under regular surveillance. Administer cautiously to patients w/ thyrotoxicosis, coronary insufficiency, hypertrophic obstructive cardiomyopathy, arterial HTN, tachyarrhythmias or DM, & in concomitant use w/ cardiac glycosides. Risk of potentially serious hypokalaemia; increased serum lactate levels & lactic acidosis after high doses; CV effects eg, myocardial ischaemia; ketoacidosis. Unwanted stimulation of cardiac adrenoceptors can occur. Potential for paradoxical bronchospasm. Can induce reversible metabolic changes eg, increased blood glucose levels. Do not drive or operate machinery in case of dizziness. Should not be used in pregnancy & lactation unless expected benefit to mother outweighs any risk to fetus or neonate.

Tenseness; headache, dizziness, fine tremor (particularly in hands); tachycardia.

Should not be prescribed w/ non-selective β-antagonists (eg, propranolol). Increased risk of CV effects w/ MAOIs, TCAs & digoxin. Discontinue salbutamol for at least 6 hr before an intended anaesth w/ halogenic anaesth. Exacerbated hypokalaemia w/ xanthine derivatives, steroids, diuretics & long-term laxatives. Theoretical potential for interaction w/ disulfiram or metronidazole because Asthalin inhaler contains ethanol.

Antiasthmatic & COPD Preparations

R03AC02 - salbutamol ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.

P₁